EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial

Eunice S Wang, Andrew A Lane, Anthony S Stein, Sumithira Vasu, Todd L Rosenblat, David A Rizzieri, Marina Konopleva, Julia Dai, Nicole R LeBoeuf, John Katsetos, Alessandra Tosolini, Naveen Pemmaraju

Acta Haematologica · 29.10.2026

DOI: 10.1159/aha/abkag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 29.10.2026. Verfasst von Eunice S Wang und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematologic malignancy, approximately 90% of patients present with skin disease. To determine whether baseline skin disease burden in BPDCN impacts efficacy and safety of first-line tagraxofusp, a subgroup analysis of a multicenter phase 1/2 trial (NCT02113982) was conducted with a modified Severity-Weighted Assessment Tool (mSWAT), an objective quantification of skin involvement utilized for response assessment.

Methods

Patients who received first-line tagraxofusp were stratified by high (n=31) or low (n=31) baseline mSWAT scores.

Results

Both groups had baseline BPDCN skin involvement (100% in mSWAT high and 90% in mSWAT low). Complete response/clinical complete response rate was 58% in both groups. Median overall survival (OS) was 25.8 (high) versus 12.0 months (low). After excluding those with prior/concomitant hematologic malignancies, median OS was 27.7 (high) versus 18.2 months (low). Among patients bridged to hematopoietic stem cell transplantation, median OS was not reached (high) versus 38.4 months (low). Adverse event profiles were similar.

Conclusion

Tagraxofusp demonstrated clinically meaningful benefit independent of baseline skin disease burden, supporting its use as first-line, standard-of-care therapy in BPDCN.

Zitieren

APA

Wang, E. S., Lane, A. A., Stein, A. S., Vasu, S., Rosenblat, T. L., Rizzieri, D. A., Konopleva, M., Dai, J., LeBoeuf, N. R., Katsetos, J., Tosolini, A., & Pemmaraju, N. (2026). Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial. Acta Haematologica. https://doi.org/10.1159/aha/abkag017

Vancouver

Wang ES, Lane AA, Stein AS, Vasu S, Rosenblat TL, Rizzieri DA, et al. Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial. Acta Haematologica. 2026. doi:10.1159/aha/abkag017

BibTeX
@article{Wang2026,
  author = {Wang, Eunice S and Lane, Andrew A and Stein, Anthony S and Vasu, Sumithira and Rosenblat, Todd L and Rizzieri, David A and Konopleva, Marina and Dai, Julia and LeBoeuf, Nicole R and Katsetos, John and Tosolini, Alessandra and Pemmaraju, Naveen},
  title = {Favorable clinical and safety outcomes independent of baseline skin disease burden in treatment-naïve blastic plasmacytoid dendritic cell neoplasm treated with tagraxofusp: a subgroup analysis of a pivotal trial},
  journal = {Acta Haematologica},
  year = {2026},
  doi = {10.1159/aha/abkag017}
}
Kostenlos starten →